Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24 vs 48 Weeks of Peginterferon/Ribavirin for HCV Genotype 1 (IL28B CC)
NCT01441804Phase 3Unknown
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- May 2011
- Primary completion
- May 2014
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of peginterferon alfa-2a, ribavirin in hepatitis C (HCV), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Status: unknown.
02
Drugs
peginterferon alfa-2aribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01441804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01441804.